Skip to main content

 Scientific publications

Liquid biopsy to test new treatment strategies in breast cancer: are we there yet?

Authors : Ignatiadis M, Piccart-Gebhart M
Year : 2012
Journal : Ann Oncol
Volume : 23(7)
Pages : 1653-5

Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling.

Authors : Azim HA, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart-Gebhart M, Sotiriou C, Loi S
Year : 2012
Journal : Clin Cancer Res
Volume : 18(5)
Pages : 1341-51

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

Authors : Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart-Gebhart M, Michiels S, Sotiriou C
Year : 2012
Journal : J. Clin. Oncol.
Volume : 30(16)
Pages : 1996-2004

External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study.

Authors : Kraan J, Sleijfer S, Strijbos MH, Ignatiadis M, Peeters D, Pierga JY, Farace F, Riethdorf S, Fehm T, Zorzino L, Tibbe AG, Maestro M, Gisbert-Criado R, Denton G, de Bono JS, Dive C, Foekens JA, Gratama JW
Year : 2011
Journal : Cytometry B Clin Cytom
Volume : 80(2)
Pages : 112-8

Outils génomiques pouvant aider au choix thérapeutique des cancers du sein – Analyse in « Cancer du Sein : compte-rendu du 12ème Cours francophone supérieur de cancérologie – (TEXTBOOK : Nice, St-Paul de Vence, Janvier 19-22, 2011 » Namer M., Héry M.

Authors : Ignatiadis M, Sotiriou C
Year : 2011
Journal : Book
Volume : -
Pages : 311-16

Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer.

Authors : Rothé F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart-Gebhart M
Year : 2011
Journal : PLoS One
Volume : 6(6)
Pages : e20980

Gene profiling assay and application: the predictive role in primary therapy.

Authors : Fumagalli D, Desmedt C, Ignatiadis M, Loi S, Piccart-Gebhart M, Sotiriou C
Year : 2011
Journal : J. Natl. Cancer Inst. Monographs
Volume : 2011(43)
Pages : 124-7

Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.

Authors : Bedard PL, Singhal SK, Ignatiadis M, Bradbury I, Haibe-Kains B, Desmedt C, Loi S, Evans DB, Michiels S, Dixon JM, Miller WR, Piccart-Gebhart M, Sotiriou C
Year : 2011
Journal : Endocr Relat Cancer
Volume : 18(6)
Pages : 721-30

Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis.

Authors : Filho OM, Ignatiadis M, Sotiriou C
Year : 2011
Journal : Crit Rev Oncol Hematol
Volume : 77(1)
Pages : 20-9

Breast cancer: Should we assess HER2 status by Oncotype DX?

Authors : Ignatiadis M, Sotiriou C
Year : 2011
Journal : Nat Rev Clin Oncol
Volume : 9(1)
Pages : 12-4

HER2-positive circulating tumor cells in breast cancer.

Authors : Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C, Metallo J, Kheddoumi N, Singhal SK, Michiels S, Veys I, Rossari J, Larsimont D, Carly B, Pestrin M, Bessi S, Buxant F, Liebens F, Piccart-Gebhart M, Sotiriou C
Year : 2011
Journal : PLoS One
Volume : 6(1)
Pages : e15624

Minimal residual disease and circulating tumor cells in breast cancer.

Authors : Ignatiadis M, Reinholz M
Year : 2011
Journal : Breast Cancer Res
Volume : 13(5)
Pages : 222